Stock Analiz

Sanara MedTech Inc. SMTI

Industrial Specialties · data as of November 13, 2026

$32.35Market cap $297M
Open the interactive analysis →

Sanara MedTech Inc. (SMTI) is a healthcare company listed in the US with a market value of about $297M. In the twelve months to September 30, 2026 it had revenue of $112M and net income of -$3M, a net margin of -2.7%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: a price to free cash flow of 40.7, 5-year revenue growth of 46% a year, a 5-year average ROIC of -6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 83% below the current price.

About Sanara MedTech

Sanara MedTech is listed in the US and classified in industrial specialties. Revenue went from $3M in 2014 to $103M in 2025, growth of about 39.6% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 9% over three years (dilution for shareholders). It spends 5% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth2/5
Track record1/5
Financial health1/5
Shareholder returns1/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 5-year revenue growth above 8% a year
  • Positive free cash flow
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%

Valuation

P/E (TTM)—
Forward P/E55.8
P/FCF40.7
P/S2.7
P/B38.8
EV/EBITDA37.8
PEG—
Dividend yield0.00%
FCF yield2.5%
Shareholder yield0.0%
Intrinsic value vs. price−83%

Growth and quality

Revenue growth (1 yr)19.0%
Revenue growth (5 yrs, per year)45.9%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-20.9%
ROIC (5-yr avg.)-5.9%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$112M$103M$87M$65M$46M$24M$16M$12M$6M$6M$6M
Net income-$3M-$38M-$10M-$4M-$8M-$8M-$4M-$3M-$600574$331309-$415747
Free cash flow$7M$2M-$229632-$4M-$6M-$5M-$5M-$2M$268660-$183757$406216
EPS (diluted)$-0.28$-4.36$-1.14$-0.52$-1.00$-1.08$-0.76$-1.32$0.00$0.00$-0.01
Net margin-2.7%-36.4%-11.2%-6.6%-17.3%-32.8%-28.5%-23.9%-10.3%5.2%-7.5%
ROIC—10.7%1.4%-5.9%-17.0%-18.8%-60.0%-30.0%-67.6%7.3%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $35.00, 8% above the current price; targets range from $35.00 to $35.00; the consensus rating is “Hold”; expected EPS is $0.20 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Sanara MedTech stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 83% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Sanara MedTech pay a dividend?

Not currently.

Is Sanara MedTech a good stock to buy?

We do not give buy or sell advice. Sanara MedTech scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.